223 related articles for article (PubMed ID: 26965184)
1. Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases.
Ettari R; Previti S; Bitto A; Grasso S; Zappalà M
Curr Med Chem; 2016; 23(12):1217-38. PubMed ID: 26965184
[TBL] [Abstract][Full Text] [Related]
2. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
3. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
[TBL] [Abstract][Full Text] [Related]
4. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
5. The immunoproteasome as a target in hematologic malignancies.
Kuhn DJ; Orlowski RZ
Semin Hematol; 2012 Jul; 49(3):258-62. PubMed ID: 22726549
[TBL] [Abstract][Full Text] [Related]
6. The immunoproteasome in antigen processing and other immunological functions.
Basler M; Kirk CJ; Groettrup M
Curr Opin Immunol; 2013 Feb; 25(1):74-80. PubMed ID: 23219269
[TBL] [Abstract][Full Text] [Related]
7. The immunoproteasome as a therapeutic target for hematological malignancies.
Miller Z; Lee W; Kim KB
Curr Cancer Drug Targets; 2014; 14(6):537-48. PubMed ID: 25059201
[TBL] [Abstract][Full Text] [Related]
8. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
[TBL] [Abstract][Full Text] [Related]
9. The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies.
Bhattarai S; Ghannam K; Krause S; Benveniste O; Marg A; de Bruin G; Xin BT; Overkleeft HS; Spuler S; Stenzel W; Feist E
J Autoimmun; 2016 Dec; 75():118-129. PubMed ID: 27522114
[TBL] [Abstract][Full Text] [Related]
10. Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads.
Kollár L; Gobec M; Proj M; Smrdel L; Knez D; Imre T; Gömöry Á; Petri L; Ábrányi-Balogh P; Csányi D; Ferenczy GG; Gobec S; Sosič I; Keserű GM
Cells; 2021 Dec; 10(12):. PubMed ID: 34943940
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
[TBL] [Abstract][Full Text] [Related]
12. The immunoproteasome: a novel drug target for autoimmune diseases.
Basler M; Mundt S; Bitzer A; Schmidt C; Groettrup M
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S74-9. PubMed ID: 26458097
[TBL] [Abstract][Full Text] [Related]
13. Immunoproteasome Function in Normal and Malignant Hematopoiesis.
Tubío-Santamaría N; Ebstein F; Heidel FH; Krüger E
Cells; 2021 Jun; 10(7):. PubMed ID: 34206607
[TBL] [Abstract][Full Text] [Related]
14. Virtual Screening Strategy and In Vitro Tests to Identify New Inhibitors of the Immunoproteasome.
Culletta G; Tutone M; Ettari R; Perricone U; Di Chio C; Almerico AM; Zappalà M
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445688
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of the immunoproteasome: current status and future directions.
Miller Z; Ao L; Kim KB; Lee W
Curr Pharm Des; 2013; 19(22):4140-51. PubMed ID: 23181576
[TBL] [Abstract][Full Text] [Related]
16. Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.
Besse A; Kraus M; Mendez-Lopez M; Maurits E; Overkleeft HS; Driessen C; Besse L
Cells; 2022 Mar; 11(5):. PubMed ID: 35269460
[TBL] [Abstract][Full Text] [Related]
17. Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes.
Ettari R; Cerchia C; Maiorana S; Guccione M; Novellino E; Bitto A; Grasso S; Lavecchia A; Zappalà M
ChemMedChem; 2019 Apr; 14(8):842-852. PubMed ID: 30829448
[TBL] [Abstract][Full Text] [Related]
18. A Nut for Every Bolt: Subunit-Selective Inhibitors of the Immunoproteasome and Their Therapeutic Potential.
Huber EM; Groll M
Cells; 2021 Jul; 10(8):. PubMed ID: 34440698
[TBL] [Abstract][Full Text] [Related]
19. On the role of the immunoproteasome in transplant rejection.
Basler M; Li J; Groettrup M
Immunogenetics; 2019 Mar; 71(3):263-271. PubMed ID: 30220008
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
Huber EM; Groll M
Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
